Related Experiment Video
Updated: Jan 19, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
Max Hardy-Werbin1, Raúl Del Rey-Vergara2, Miguel Alejandro Galindo-Campos3
1Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), 08003 Barcelona, Spain. mhardy@imim.es.
Abstract:
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Within the potentially interesting targets, the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway activation is associated with worse survival and chemoresistance in SCLC. Preclinical data suggest that the inhibition of the MET pathway can revert chemoresistance and prevent tumor growth. Recently, immunotherapy has shown modest but relevant activity in SCLC. Interestingly, MET modulation seems to be involved in increasing the efficacy of standard checkpoint inhibitors. Here, we review the preclinical and clinical data of MET inhibition in SCLC, and the role of this pathway in the immune response.
Insights
Targeting the MET pathway shows promise for treating aggressive small cell lung cancer (SCLC). MET inhibition may improve survival and enhance immunotherapy effectiveness in advanced SCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Small cell lung cancer (SCLC) remains highly aggressive with limited treatment advancements.
- Hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway activation correlates with poor prognosis and chemoresistance in SCLC.
- Current targeted therapies have not demonstrated significant efficacy in SCLC.
Purpose of the Study:
- To review preclinical and clinical evidence for MET pathway inhibition in SCLC.
- To explore the role of MET signaling in SCLC chemoresistance and immune response.
- To assess the potential of MET inhibitors in combination with immunotherapy for SCLC.
Main Methods:
- Review of preclinical studies investigating MET pathway inhibitors in SCLC models.
- Analysis of clinical trial data evaluating MET-targeted agents in SCLC.
- Examination of research on the interplay between MET signaling and the tumor immune microenvironment in SCLC.
Main Results:
- Preclinical data indicate MET pathway inhibition can overcome chemoresistance and inhibit SCLC growth.
- MET pathway activation is linked to worse survival and resistance to systemic therapies in SCLC.
- Emerging evidence suggests MET modulation may enhance the efficacy of immunotherapy in SCLC.
Conclusions:
- MET pathway inhibition represents a promising therapeutic strategy for SCLC.
- Targeting MET could potentially re-sensitize SCLC to chemotherapy and improve outcomes.
- Combining MET inhibitors with checkpoint inhibitors may offer a novel approach to treating advanced SCLC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...